Dynavax (NASDAQ: DVAX) reported Q2 EPS of $0.14, $0.04 better than the analyst estimate of $0.10. Revenue for the quarter came in at $95.44 million versus the consensus estimate of $85.57 million.

FULL YEAR 2025 FINANCIAL GUIDANCE
Dynavax is updating its full year 2025 financial guidance, based on its current operating plan:

HEPLISAV-B net product revenue is expected in the range of $315 to $325 million, an increase compared to the prior range of $305 to $325 million.
Adjusted EBITDA* is expected to be at least $75 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.